Literature DB >> 1319827

Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma.

T Oda1, H Tsuda, A Scarpa, M Sakamoto, S Hirohashi.   

Abstract

Hepatocellular carcinoma, sometimes shows multiple tumor nodules, therefore poses a problem of differential diagnosis between cancers of multifocal and those of metastatic origin. Conventionally, pathological criteria have been used for this purpose, but these are largely subjective. In order to facilitate more objective differential diagnosis of multiple hepatocellular carcinoma, we used the pattern of mutation of the p53 gene as a marker for each tumor nodule. We studied 58 nodules from 26 cases of multiple hepatocellular carcinoma using polymerase chain reaction-single strand conformation polymorphism analysis, a simple method for detecting mutations. p53 gene mutations were detected in 65% (17 of 26) of cases. The internodule mutation patterns were heterogeneous in 11 cases and homogeneous in 6, enabling a multifocal origin to be diagnosed in the former and a metastatic origin in the latter at the genetic level. Moreover, the origin of recurrent tumors was determined from the mutation pattern. It is concluded that analysis of p53 mutations seems to be useful for differentiating the origin of multiple cancers, since the information it yields is essentially objective.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319827

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma.

Authors:  K Ashida; Y Kishimoto; K Nakamoto; K Wada; G Shiota; Y Hirooka; Y Kamisaki; T Itoh; H Kawasaki
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Determination of primary foci of metastatic tumors by p53 mutational analysis in intraesophageal multiple carcinomas.

Authors:  S Kuwabara; T Nishimaki; Y Ajioka; S Komukai; T Suzuki; H Watanabe; K Hatakeyama
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

3.  Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.

Authors:  S D Ryder; P M Rizzi; M Volkmann; E Metivier; L M Pereira; P R Galle; N V Naoumov; H Zentgraf; R Williams
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

4.  Influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  P S Russell
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

5.  Expression of mutant p53 protein in hepatocellular carcinoma.

Authors:  J D Collier; M Carpenter; A D Burt; M F Bassendine
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

6.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

7.  Investigation of chromosomal aberrations in Egyptian hepatocellular carcinoma patients by fluorescence in situ hybridization.

Authors:  Magdy S Aly; Abeer A Bahnassy; Zekri N Abdel-Rahman
Journal:  Indian J Hum Genet       Date:  2010-05

8.  Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease.

Authors:  R K Gupta; K Patel; W F Bodmer; J G Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma.

Authors:  M Zhao; N X Zhang; J A Laissue; A Zimmermann
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

10.  Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations.

Authors:  A Scarpa; P Capelli; G Zamboni; T Oda; K Mukai; F Bonetti; G Martignoni; C Iacono; G Serio; S Hirohashi
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.